STOCK2S 26016 structure
|
Common Name | STOCK2S 26016 | ||
|---|---|---|---|---|
| CAS Number | 332922-63-1 | Molecular Weight | 333.38 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C20H19N3O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of STOCK2S 26016STOCK2S-26016 is a WNK signalling inhibitors. STOCK2S-26016 inhibits WNK4 and WNK1 with the IC50s of 16 μM and 34.4 μM, respectively. STOCK2S-26016 has potential for antihypertensive research[1]. |
| Name | STOCK2S-26016 |
|---|
| Description | STOCK2S-26016 is a WNK signalling inhibitors. STOCK2S-26016 inhibits WNK4 and WNK1 with the IC50s of 16 μM and 34.4 μM, respectively. STOCK2S-26016 has potential for antihypertensive research[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 16 μM (WNK4); 34.4 μM (WNK1)[1] |
| In Vitro | STOCK2S-26016 (10 and 30 minutes) blocks the effect of L-NAME on phosphorylated sodium-chloride cotransporter (NCC) in mDCT cells[2]. STOCK2S-26016 (25-200 μM) drastically and dose-dependently reduces the phosphorylation of STE20/SPS1-related proline/alanine-rich protein kinase (SPAK) and NCC in mpkDCT cells[1]. STOCK2S-26016 (50-200 μM) drastically and dose-dependently reduces the phosphorylation of SPAK and Na/K/Cl cotransporter 1 (NKCC1) in MOVAS cells[1]. |
| References |
| Molecular Formula | C20H19N3O2 |
|---|---|
| Molecular Weight | 333.38 |